CD274 and esophageal squamous cell carcinoma: When serplulimab was reduced to 30% of the current price ($264.65 per 100mg), the probabilities of serplulimab plus chemotherapy being cost-effective were 81.42%, 67.74% and 96.75% in advanced ESCC patients with PD-L1-positive, PD-L1 1≤CPS<10 and CPS≥10, respectively (Supplementary Figures S2, S3).